New York and Chicago based Lupus Research Institute (LRI) says its supporters and others have much to celebrate in a 2015 Omnibus Appropriations Bill passed in the House and Senate and signed into law by President Obama in mid-December. “We are proud that the strong presence of LRI patient…
The Lupus Research Institute (LRI) recently announced this years’Â research grants awarded to systemic lupus erythematosus (SLE) researchers. The topics vary, but all strive to either present a better understanding of why people develop lupus or to improve treatment for the disease. Two projects will investigate the link between bacteria…
Yale researchers have discovered a new transcription factor governing the production of a gene related to conditions such as systemic lupus erythematosus (SLE). The discovery opens up the possibility of more personalized SLE treatment. The study, titled “Transcription factor ICBP90 regulates the MIF promoter and immune susceptibility locus“ and published in the …
A recent study has identified two novel substances — an antioxidant and an anti-inflammatory agent — that can control the excessive inflammatory response to fungal infection often seen in patients with systemic lupus erythematosus (SLE). Earlier studies have shown that invasive fungal infection (IFI) with the fungus Candida albicans can be life-threatening for SLE patients.
XTL Biopharmaceuticals has announced it has submitted the full protocol for its advanced stage clinical trial of hCDR1 in the treatment of systemic lupus erythematosus (SLE, commonly referred to as lupus) to Yeda Research and Development Company in Israel. According to the Phase II clinical study titled “Safety…
Neovacs announced it has concluded a four-year, €5 million ($5.5 million) non-dilutive funding agreement to finalize clinical development and start the production process for its therapeutic IFN Kinoid vaccine. The funding, in the form of grants and repayable advances, came through a decision of The General Commission for Investment, operated by Bpifrance, a subsidiary of the French…
Dutch biopharmaceutical company argenx recently announced the completion of the dose-escalation stage of a Phase 1 clinical trial exploring its drug candidate ARGX-113, a potential breakthrough therapy for treatment of exacerbations of IgG-mediated autoimmune diseases, including systemic lupus erythematosus (SLE). Preliminary data of the trial demonstrated a favorable safety and tolerability profile…
Atherosclerosis is highly prevalent among Danish patients with systemic lupus erythematosus (SLE) without any history of cardiovascular disease (CVD), researchers at Odense University Hospital reported, further noting that the evaluation of more than one vascular territory was necessary to diagnose the disease in these patients. Their research paper, titled “Coronary, Carotid, and Lower-extremity…
A recent systematic review, published in the International Journal of Chronic Diseases, revealed the prevalence of the central nervous system (CNS) involvement — rather than the peripheral nervous system (PNS) — in connective tissue disorders like systemic lupus erythematosus. But more research is needed to understand whether these CNS…
The development of new drugs to treat systemic lupus erythematosus (SLE), in comparison to autoimmune diseases like rheumatoid arthritis, has been excruciatingly slow. Benlysta (belimumab) is the rare exception, the only  SLE drug approved by the U.S. Food and Drug Administration (FDA) in the past 50 years. A biomarker assay for SLE…